Adaptive Biotechnologies Corporation Share Price

Adaptive Biotechnologies Corporation Share Price

NASDAQ: ADPT | Mid Cap
$28.36
-$0.01 (-0.02%) Last updated on 29 Oct, 2026 | 20:38 IST
  • Performance
  • Chart
  • Fundamentals
  • Quarterly P&L
  • Annual P&L
  • About
  • Price history
  • FAQs

Adaptive Biotechnologies Corporation Stock Performance

Open
$28.61
Prev. Close
$28.37
Circuit Range
N/A
Day Range
$28.18 - $28.80
Year Range
$12.01 - $30.74
Volume
13,256
Average Traded
$28.50

Adaptive Biotechnologies Corporation Share Price Today

As of 29 October 2026, Adaptive Biotechnologies Corporation's share price is $28.36. The stock opened at $28.61, compared to its previous close of $28.37. During today's trading session, Adaptive Biotechnologies Corporation's share price traded between $28.18 and $28.80, with an average price of $28.49. Over the past 52 weeks, the stock has recorded a high of $30.74 and a low of $12.01. In terms of performance, Adaptive Biotechnologies Corporation's share price has risen by 101.24% over the last six months and is up 63.20% on a year-on-year basis.

Adaptive Biotechnologies Corporation Share Price Chart

Line chart of the Adaptive Biotechnologies Corporation price trend over the selected period. The price fell overall, ranging from 28.18 to 28.80, ending at 28.36.
$28.18$28.80
L
Show Current Price
H

Adaptive Biotechnologies Corporation Stock Fundamentals & Key Indicators

Market Cap
$4.30B
PE Ratio (TTM)
N/A
Dividend Yield
0.00%
EPS (TTM)
$-0.40
Revenue (TTM)
$276.98B
Return On Equity (TTM)
-44.68%
Profit Margin
-21.48%
Debt to Equity
2.34
Quarterly Earnings Growth YoY
-516.65%

Adaptive Biotechnologies Corporation Quarterly Profit & Loss

All figures in USD

ParticularsSep 2025Dec 2025Mar 2026Jun 2026
Revenue$93.97$71.68$70.87$71.55
Net Profit$9.55-$13.58-$20.03-$39.79
Net Profit Margin10.16%-18.95%-28.26%-55.61%
Income ChangeN/A-242.20%-47.50%-98.65%

Adaptive Biotechnologies Corporation Annual Profit & Loss

All figures in USD

Particulars2022202320242025
Revenue$185.31$170.28$178.96$276.98
Net Profit-$200.19-$225.25-$159.49-$59.50
Net Profit Margin-108.03%-132.28%-89.12%-21.48%
Income ChangeN/A-12.52%29.19%62.69%

About Adaptive Biotechnologies Corporation

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment.

Adaptive Biotechnologies Corporation Historical Returns

Share price history by day, with open and close prices and the day's change
MonthOpenCloseChange %
Oct 2026
$28.82
$28.31
-2.16%
Sep 2026
$24.93
$28.93
+9.48%
Aug 2026
$22.88
$26.43
+17.10%
Jul 2026
$21.46
$22.57
+5.32%
Jun 2026
$14.97
$21.43
+41.45%
May 2026
$14.34
$15.15
+7.48%
Apr 2026
$14.09
$14.10
+1.51%
Mar 2026
$15.74
$13.88
-13.44%
Feb 2026
$18.36
$16.04
-13.30%
Jan 2026
$16.27
$18.50
+13.95%
Dec 2025
$19.28
$16.23
-17.42%
Nov 2025
$17.30
$19.66
+13.12%

ADPT Share Price FAQs